Literature DB >> 18041899

Nitazoxanide: clinical studies of a broad-spectrum anti-infective agent.

Saima Aslam1, Daniel M Musher.   

Abstract

Nitazoxanide is a new compound with broad-spectrum activity against numerous intestinal protozoa, helminths and anaerobic bacteria. It is approved for the treatment of diseases caused by Giardia intestinalis and Cryptosporidium species. The drug is well tolerated, with few side effects and requires a short course of treatment. Further investigations regarding its use in patients with AIDS is needed. Nitazoxanide represents a significant advance in the treatment of intestinal parasitic infections worldwide.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 18041899     DOI： 10.2217/17460913.2.6.583

Source DB:  PubMed          Journal:  Future Microbiol        ISSN： 1746-0913            Impact factor:   3.165


  10 in total

1.  Thiazolides promote G1 cell cycle arrest in colorectal cancer cells by targeting the mitochondrial respiratory chain.

Authors:  P Ripani; J Delp; K Bode; M E Delgado; L Dietrich; V M Betzler; N Yan; G von Scheven; T U Mayer; M Leist; T Brunner
Journal:  Oncogene       Date:  2019-12-16       Impact factor: 9.867

2.  Nitazoxanide: Jack of All, Master of None?

Authors:  Rishi Bolia
Journal:  Indian J Pediatr       Date:  2019-12-04       Impact factor: 1.967

3.  The Effects of Commercially Available Syzygium aromaticum, Anethum graveolens, Lactobacillus acidophilus LB, and Zinc as Alternatives Therapy in Experimental Mice Challenged with Cryptosporidium parvum.

Authors:  Mona Gaber; Lamia Ahmed A Galal; Haiam Mohamed Mahmoud Farrag; Dalia M Badary; Samia S Alkhalil; Nahed Elossily
Journal:  Infect Drug Resist       Date:  2022-01-20       Impact factor: 4.177

Review 4.  Clinical significance of enteric protozoa in the immunosuppressed human population.

Authors:  D Stark; J L N Barratt; S van Hal; D Marriott; J Harkness; J T Ellis
Journal:  Clin Microbiol Rev       Date:  2009-10       Impact factor: 26.132

5.  Efficacy of nitazoxanide against clinical isolates of Mycobacterium tuberculosis.

Authors:  Kristina Shigyo; Oksana Ocheretina; Yves Mary Merveille; Warren D Johnson; Jean William Pape; Carl F Nathan; Daniel W Fitzgerald
Journal:  Antimicrob Agents Chemother       Date:  2013-03-18       Impact factor: 5.191

Review 6.  Epidemiology and control of human gastrointestinal parasites in children.

Authors:  Michael O Harhay; John Horton; Piero L Olliaro
Journal:  Expert Rev Anti Infect Ther       Date:  2010-02       Impact factor: 5.091

7.  Could nitazoxanide be added to other essential medicines for integrated neglected tropical disease control and elimination?

Authors:  Peter J Hotez
Journal:  PLoS Negl Trop Dis       Date:  2014-03-27

8.  Fascioliasis and intestinal parasitoses affecting schoolchildren in Atlixco, Puebla State, Mexico: epidemiology and treatment with nitazoxanide.

Authors:  José Lino Zumaquero-Ríos; Jorge Sarracent-Pérez; Raúl Rojas-García; Lázara Rojas-Rivero; Yaneth Martínez-Tovilla; María Adela Valero; Santiago Mas-Coma
Journal:  PLoS Negl Trop Dis       Date:  2013-11-21

9.  Targeting intracellular Leishmania (L.) infantum with nitazoxanide entrapped into phosphatidylserine-nanoliposomes: An experimental study.

Authors:  Erika Gracielle Pinto; Leandro R S Barbosa; Renato A Mortara; Andre Gustavo Tempone
Journal:  Chem Biol Interact       Date:  2020-10-20       Impact factor: 5.192

10.  Synthesis and antiplasmodial assessment of nitazoxanide and analogs as new antimalarial candidates.

Authors:  Camila Irabuena; Laura Scarone; Guilherme Eduardo de Souza; Anna Caroline Campos Aguiar; Giovana Rossi Mendes; Rafael Victorio Carvalho Guido; Gloria Serra
Journal:  Med Chem Res       Date:  2022-01-28       Impact factor: 1.965
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.